{Reference Type}: Journal Article
{Title}: Injectable butyrate-prodrug micelles induce long-acting immune modulation and prevent autoimmune arthritis in mice.
{Author}: Cao S;Budina E;Wang R;Sabados M;Mukherjee A;Solanki A;Nguyen M;Hultgren K;Dhar A;Hubbell JA;
{Journal}: J Control Release
{Volume}: 372
{Issue}: 0
{Year}: 2024 Jun 24
{Factor}: 11.467
{DOI}: 10.1016/j.jconrel.2024.06.027
{Abstract}: Short chain fatty acid (SCFAs), such as butyrate, have shown promising therapeutic potential due to their immunomodulatory effects, particularly in maintaining immune homeostasis. However, the clinical application of SCFAs is limited by the need for frequent and high oral dosages. Rheumatoid arthritis (RA) is characterized by aberrant activation of peripheral T cells and myeloid cells. In this study, we aimed to deliver butyrate directly to the lymphatics using a polymeric micelle-based butyrate prodrug to induce long-lasting immunomodulatory effects. Notably, negatively charged micelles (Neg-ButM) demonstrated superior efficacy in targeting the lymphatics following subcutaneous (s.c.) administration and were retained in the draining lymph nodes, spleen, and liver for over one month. In the collagen antibody-induced arthritis (CAIA) mouse model of RA, only two s.c. injections of Neg-ButM successfully prevented disease onset and promoted tolerogenic phenotypes in T cells and myeloid cells, both locally and systemically. These results underscore the potential of this strategy in managing inflammatory autoimmune diseases by directly modulating immune responses via lymphatic delivery.